



MSCO News

January 2020

Dedicated
to improving
cancer care and
treatment
together



Massachusetts Society of
Clinical Oncologists

MSCO welcomes fellows to submit applications for travel assistance grants to NCCN's Fellows Program and Annual Meeting from March 19-22, 2020. Details can be found [HERE](#). Applications due by February 1, 2020. Questions and applications can be sent to nstrunk@mms.org

MSCO @ NCCN - Fellows Travel Assistance Grant Deadline – February 1, 2020

Purpose and Scope of MSO @ NCCN - Fellows Travel Assistance Grant:

The purpose of the grant is to assist in the professional development of oncology fellows in the state of Massachusetts by offering an opportunity to learn more about the clinical and business aspects of practicing oncology at the NCCN Annual Conference. MSO will offer up to two grants to fellows to cover some expenses to attend the NCCN Fellows Program and Pre-Conference on Thursday, March 19, 2020 and the NCCN Annual Conference from Friday, March 20 to Sunday, March 22, 2020 in Orlando, FL.

Requirements:

- Applicants must be a member of MSO
- Applicants must attend MSO Annual Meeting 2020
- Applicants must be an oncology fellow
- Applicants agree to meet with MSO representatives at a preset time/location while at NCCN Annual Meeting

Funding:

- Up to \$1,500 (receipts required) to help cover the following:
 - o Roundtrip Airfare to Orlando
 - o Hotel for up to 3 nights
 - o Transportation to and from airport
 - o Food

Application Guidelines:

- Submit a Statement of Purpose (not to exceed 500 words)
- Submit a curriculum vitae

Submission

- Questions can be directed to Nathan Strunk at nstrunk@mms.org or 781-434-7329
- Please submit applications to mso@mms.org

Upcoming Events



NNECOS
Lunchtime
BEST ONCOLOGY PRACTICE
SERIES

THE ENCORE
PRESENTATION SERIES!
CNE CREDIT AVAILABLE*

RECONSIDERING CANCER
SURVIVORSHIP IN OUR
AGED SOCIETY:
IMPROVING PATIENT
EXPERIENCE AND
CLINICAL CARE

Thursday
February 13th
nneCOS.org/lunchtime

MSCO encourages members to join the NNECOS (Northern New England Clinical Oncology Society) free lunchtime webinar on **Thursday, February 13th**, which will be an encore presentation of "**Reconsidering Cancer Survivorship in Our Aged Society**," by Sarah Kagan, PhD, RN. Register [HERE](#).

MSCO looks forward to hosting **Dr. Robert Carlson, MD**, CEO of NCCN, on the evening of Wednesday, May 6th, 2020 on the "**Future of Pathways**." More details coming soon, but set a reminder in your calendar [HERE](#).



FDA Approvals

The U.S. Food and Drug Administration approved **pembrolizumab (Keytruda; Merck)** for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. [Read full press release.](#)

The U.S. Food and Drug Administration granted accelerated approval to **fam-trastuzumab deruxtecan-nxk (Enhertu; Daiichi Sankyo)** for patients combination with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. [Read full press release.](#)

The U.S. Food and Drug Administration granted accelerated approval to **tazemetostat (Tazverik; Epizyme)** for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. [Read full press release.](#)

The U.S. Food and Drug Administration approved **olaparib (Lynparza; AstraZeneca)** for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma, as detected by an FDA-approved test, whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. [Read full press release.](#)

The U.S. Food and Drug Administration granted accelerated approval to **enfortumab vedotin-ejfv (Padcev; Astellas)** for adult patients with locally advanced or metastatic urothelial cancer who have

previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant , locally advanced or metastatic setting.

[Read full press release.](#)

Get the latest updates, follow MSCO on social media



If you wish to unsubscribe to the newsletter, please click [here](#).